Table 2 Treatment-emergent adverse events, including immune-related adverse events (irAEs), graded according to CTCAE v5.0.
Adverse Event | Any Grade n (%) | Grade 1 n (%) | Grade 2 n (%) | Grade 3 n (%) | Grade 4 n (%) |
|---|---|---|---|---|---|
Anaemia | 69 (62.2) | 24 (21.6) | 38 (34.2) | 7 (6.3) | 0 (0.0) |
Leukocytosis | 32 (28.8) | 8 (7.2) | 14 (12.6) | 8 (7.2) | 2 (1.8) |
Leukopenia | 34 (30.6) | 13 (11.7) | 15 (13.5) | 5 (4.5) | 1 (0.9) |
Neutropenia | 18 (16.2) | 0 (0.0) | 7 (6.3) | 5 (4.5) | 6 (5.4) |
Thrombocytopenia | 19 (17.1) | 11 (9.9) | 5 (4.5) | 3 (2.7) | 0 (0.0) |
Thrombocytosis | 17 (15.3) | 9 (8.1) | 7 (6.3) | 1 (0.9) | 0 (0.0) |
Hyponatremia | 36 (32.4) | 26 (23.4) | 6 (5.4) | 4 (3.6) | 0 (0.0) |
Hyperglycemia | 22 (19.8) | 14 (12.6) | 4 (3.6) | 4 (3.6) | 0 (0.0) |
Hypothyroidism | 13 (11.7) | 5 (4.5) | 4 (3.6) | 2 (1.8) | 2 (1.8) |
Elevated ALT | 17 (15.3) | 9 (8.1) | 7 (6.3) | 0 (0.0) | 1 (0.9) |
Elevated AST | 11 (9.9) | 6 (5.4) | 3 (2.7) | 1 (0.9) | 1 (0.9) |
AKI | 13 (11.7) | 11 (9.9) | 2 (1.8) | 0 (0.0) | 0 (0.0) |
Hyperthyroidism | 6 (5.4) | 5 (4.5) | 1 (0.9) | 0 (0.0) | 0 (0.0) |
Hypoalbuminemia | 9 (8.1) | 6 (5.4) | 2 (1.8) | 1 (0.9) | 0 (0.0) |
Hypocalcemia | 3 (2.7) | 1 (0.9) | 0 (0.0) | 1 (0.9) | 1 (0.9) |
Hyperbilirubinemia | 6 (5.4) | 4 (3.6) | 1 (0.9) | 1 (0.9) | 0 (0.0) |
Hypoproteinemia | 8 (7.2) | 6 (5.4) | 2 (1.8) | 0 (0.0) | 0 (0.0) |
CINV | 8 (7.2) | 1 (0.9) | 4 (3.6) | 3 (2.7) | 0 (0.0) |
Mucositis oral | 7 (6.3) | 0 (0.0) | 5 (4.5) | 2 (1.8) | 0 (0.0) |
Diarrhoea | 5 (4.5) | 1 (0.9) | 4 (3.6) | 0 (0.0) | 0 (0.0) |
Fatigue | 2 (1.8) | 0 (0.0) | 2 (1.8) | 0 (0.0) | 0 (0.0) |
Febrile Neutropenia | 1 (0.9) | 0 (0.0) | 0 (0.0) | 1 (0.9) | 0 (0.0) |
Rash | 1 (0.9) | 1 (0.9) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
